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P U B L I S H E D B Y E L S E V I E R I N C .LettersColchicine for
Post-Operative
Pericardial Effusion
Preliminary Results of the POPE-2 StudyThe incidence of pericardial effusion is high after
cardiac surgery. It peaks at the end of the ﬁrst post-
operative week and usually decreases spontane-
ously. Tamponade occurs in 1% to 2% of patients.
Early tamponade (occurring during the ﬁrst 7 post-
operative days) is due to surgical bleeding. How-
ever, most tamponade cases occur more than 7 days
after surgery (1) and may develop slowly without
clear-cut clinical signs in asymptomatic patients.
This situation is disconcerting because patients
often have been discharged from the hospital by
this time.
Traditionally, inﬂammation is considered to be
involved in these late post-operative pericardial
effusion events, even though a randomized study
(2) showed that nonsteroidal anti-inﬂammatory drugs
were not effective for post-operative pericardial
effusions persisting >7 days after surgery and pre-
venting late cardiac tamponade. Colchicine is an anti-
inﬂammatory drug that is effective in treating acute
pericarditis (3). Furthermore, if colchicine is admin-
istered before or within 3 days after surgery, it helps
prevent post-pericardiotomy syndrome, an inﬂam-
matory post-injury pericardial syndrome that usually
mimics acute pericarditis, which often involves a
small pericardial effusion and with an evolution
that is usually spontaneously benign (4). However,
colchicine has not been tested for actual post-
operative pericardial effusions; therefore, whether
the drug reduces their volume and prevents late
cardiac tamponade is unknown. A high rate of gas-
trointestinal adverse effects and drug discontinua-
tions limits the clinical applicability of colchicine in
early perioperative care (4). This is why we performed
a randomized, double-blinded, placebo-controlled,
parallel-group study comparing the efﬁcacy of col-
chicine and placebo in reducing (POPE) the volume ofpost-operative pericardial effusion in patients with
post-operative effusion persisting >7 days after heart
surgery (POPE study).
We performed a ﬁrst transthoracic echocardiogra-
phy in 8,140 consecutive patients 7 to 30 days after
cardiac surgery. Pericardial effusions were classiﬁed
into 4 grades, by size and site: grade 1 (minimal),
loculated effusion <10 mm; grade 2 (moderate),
loculated effusion 10 to 14 mm or circumferential
effusion <10 mm; grade 3 (medium sized), loculated
effusion 15 to 19 mm or circumferential effusion 10
to 14 mm; and grade 4 (large), loculated effusion
$20 mm or circumferential effusion $15 mm. We
included patients only if they showed pericardial
effusion of grade 2 or worse (n ¼ 252); 55 were
excluded (mainly for consent refusal, indication for
immediate pericardial drainage, or colchicine con-
traindication). Finally, 197 patients (172 were needed
by assuming that the spontaneous decrease in mean
pericardial effusion grade would be 0.6 grade [5])
were enrolled 16.2  5.3 days after surgery: 98
were randomly assigned to receive colchicine, 1 mg
per day, and 99 placebo, for 14 days. The primary
endpoint was the difference between treatment
groups in mean decrease in pericardial effusion
grade from baseline by Mann-Whitney U test on an
intent-to-treat basis for all 197 patients. Ten patients
in the colchicine group and 3 in the placebo group
stopped therapy before the end of the study because
of new symptoms (mainly digestive) or late with-
drawal of consent. However, we obtained baseline
and follow-up echocardiograms and clinical follow-
up for all.
The 2 groups did not differ in clinical characteris-
tics, type of surgery, or background treatment. The
mean age was approximately 64 years, and 86%
were male. Surgeries performed were coronary artery
bypass graft (n ¼ 110), aortic valve replacement
(n ¼ 82), mitral valve surgery (n ¼ 26), and ascending
aorta replacement (n ¼ 30); 50 patients had under-
gone combined surgeries.
Mean pericardial effusion grades at inclusion were
2.9  0.8 and 3.0  0.8 for the placebo and colchicine
groups, respectively (p ¼ 0.46), which conﬁrms the
large mean pericardial effusion volume at inclusion.
FIGURE 1 Mean Pericardial Effusion Grade Decrease: Comparison Between Colchicine and Placebo Groups
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Values are mean  SD and (median [25th;75th interquartile range]). Echo ¼ echocardiography.
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1199The main endpoint, mean decrease in pericardial
effusion grade from baseline, was 1.1  1.3
and 1.3  1.3, respectively (mean difference between
groups 0.19; 95% CI: 0.55 to 0.16; p ¼ 0.23)
(Figure 1).
In conclusion, among patients with moderate to
severe pericardial effusion persisting >7 days after
cardiac surgery, colchicine administration did not
have a signiﬁcant effect on evolution of the effusion.
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